TY - JOUR T1 - Dr. Yoshida, <em>et al</em> reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 1253 LP - 1253 DO - 10.3899/jrheum.160194 VL - 43 IS - 6 AU - KAZUKI YOSHIDA AU - MITSUMASA KISHIMOTO AU - DANIEL H. SOLOMON Y1 - 2016/06/01 UR - http://www.jrheum.org/content/43/6/1253.2.abstract N2 - To the Editor:We thank Dr. Kawada1 for his interest in our studies2. Since the landmark RRR study3, the field of biological disease-modifying antirheumatic drug (bDMARD) discontinuation study has expanded tremendously4,5,6. However, as Dr. Kawada pointed out, the design of studies varies widely6, making comparison of studies difficult. One important point that has … Address correspondence to Dr. K. Yoshida, Department of Epidemiology, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, Massachusetts 02115, USA. E-mail: kazukiyoshida{at}mail.harvard.edu ER -